Supplementary Online Content

Frezza MA, Jones R, Vullo SL, Asano N, et al. Anthracycline, gemcitabine, and pazopanib in epithelioid sarcoma: a multi-institutional case series [published online April 12, 2018]. *JAMA Oncol.* doi:10.1001/jamaoncol.2018.0219

This supplementary material has been provided by the authors to give readers additional information about their work.

e-Table 1. Treatment details.

	Anthracycline-based (N=85)	Gemcitabine-based (N=41)	Pazopanib (N=18)
Number of selected regimens			
• 1	63 (74%)	22 (54%)	6 (33%)
• 2	17 (20%)	14 (34%)	7 (39%)
• 3	5 (6%)	5 (12%)	5 (28%)
Treatment completed (%)	85 (100%)	41 (100%)	18 (100%)
• PD	45 (53%)	28 (68%)	17 (94%)
• Toxicity	5 (6%)	5 (12%)	1 (6%)
• Other reasons	35 (41%)	8 (20%)	0
Evaluable for response (%)	85 (100%)	41 (100%)	18 (100%)
Median number of previous lines (range)	0 (0-2)	1 (0-5)	2 (1-4)
Median number of cycles (range)	5 (1-14)	4 (1-15)	2 (1-26)
Median number of following lines (range)	1 (0-6)	1 (0-3)	0 (0-3)

PD: progressive disease; A: anthracycline single agent; AI: anthracycline and ifosfamide; G: gemcitabine single agent; GD: gemcitabine and docetaxel.

e-Table 2. Regimens used and corresponding response rate.

	Regimen used	Response rate
Anthracycline-based (N=85)	An: 20 (24%) An/I: 45 (52%) An/other: 20 (24%)	An: 25% (5/20) An/I: 27% (12/45) An/other: 10% (2/20)
Gemcitabine-based (N=41)	G: 3 (9%) GD: 35 (82%) Other: 3 (9%)	G: 33% (1/3) G/D: 29% (10/35) G/other: 0
Pazopanib (N=18)	-	-

e-Table 3. Response rate, median progression-free survival, and median overall survival by morphological subtype, primary site, and response to treatment.

Group	End-point	Morphological subtype	Primary site	Response to treatment
Ab-regimens	RR (%)	CT: 19% PT: 26% *P-value=0.44*	DP: 18% PP: 26% *P-value=0.43*	-
	Median PFS (IQR), *months*	CT: 7 (3.3 - 10.5) PT: 5 (2.2 - 9.7) *P-value= 0.52*	DP: 6 (3 - 12.0) PP: 6 (2.3 – 10.1) *P-value= 0.52*	NR: 5 (2.2 - 9.2) R: 9 (4.6 - 20.6) *P-value= 0.01*
	Median OS (IQR), *months*	CT: 18 (8.4 - 26.0) PT: 15 (8.7 - 33.1) *P-value= 0.34*	DP: 15 (8.4 - 23.8) PP: 16 (8.7 - 33.1) *P-value= 0.79*	NR: 16 (8.4-25.2) R: 21 (10.4 - 34.9) *P-value= 0.29*
Gb-regimens	RR (%)	CT: 30% PT: 22% *P-value=0.72*	DP: 40% PP: 14% *P-value=0.08*	-
	Median PFS (IQR), *months*	CT: 5 (2.3-10) PT: 4 (1.7-11.9) *P-value= 0.78*	DP: 6 (2.7 - 10.0) PP: 3 (1.7 - 11.9) *P-value= 0.82*	NR = 3 (1.7 - 6.2) R = 16 (7.1 - N.E.) *P-value= 0.0004*
	Median OS (IQR), *months*	CT: 20 (9.6 - 37.3) PT: 14 (6.0 - 50.2) *P-value= 0.5*	DP: 20 (9.6-37.3) PP: 18 (6.0-50.2) *P-value= 0.67*	NR: 14 (5.4 - 24.9) R: 32 (20.3 - 43.8) *P-value= 0.10*
Pazopanib	RR (%)	-	-	-
	Median PFS (IQR), *months*	CT: 3 (1.7 - 11.0) PT: 4 (2.2 - 17.1) *P-value= 0.78*	DP: 5 (1.7 - 17.1) PP: 3 (2.4 - 7.6) *P-value= 0.34*	-
	Median OS (IQR), *months*	CT: 14 (5.0 - 28.9) PT: 20 (4.6 - 33.1) *P-value= 0.68*	DP: 20 (5.2 - 33.1) PP: 8 (4.8 - 42.7) *P-value= 0.35*	-

RR: response rare; PFS: progression free survival; OS: overall survival; CT: classic-type; PT: proximal-type; DP: distal primary site; PP: proximal primary site; R: responding patients; NR: not responding patients.

e-Table 4. Population outcome.

	Anthracycline-based (N=85)	Gemcitabine-based (N=41)	Pazopanib (N=18)
Median OS from the diagnosis (IQR)	33 (15-75)	62 (20-152)	60 (18-152)
Median follow-up (IQR)	88 months (27–210)	22 months (14–NE)	33 months (19-NE)
Patients status (%) • **Dead** • **Alive with disease** • **No evidence of disease**	 68 (80%) 14 (16%) 3 (4%)	 26 (63%) 14 (34%) 1 (4%)	 13 (72%) 5 (28%) 0
Lost at follow-up (%)	8 (9%)	4 (9%)	1 (6%)